Universal Robots launches Gen 7 robotics platform at IMTS

Universal Robots, a subsidiary of Teradyne, Inc. (NASDAQ: TER), introduced its seventh-generation robotics platform, Gen 7, at the IMTS tradeshow in Chicago, according to a company press release.

The platform includes three new g-Series robot arms — the UR10g-1750, UR17g-1300, and UR18g-950 — named after their payload in kilograms and reach in millimeters. The arms feature a redesigned tool flange with built-in force-torque sensing, impedance control, and Real-Time Data Exchange capability. The flange is designed to connect cameras and high-bandwidth sensors without external cabling.

Gen 7 also introduces the CB7 Core controller, which the company says offers 40% more compute power in a 30% smaller footprint than previous generations. The controller supports multi-network communication and is compatible with existing e-Series and UR Series robot arms. It is available in a standalone control box version and a compact cabinet-integration version.

The platform runs on the PolyScope X operating system, which includes open APIs, ROS2 communication, ISO 10218-1 safety functionality, and cybersecurity compliance. A new TP7 Core teach pendant, described as more than 20% lighter than previous models, and an SP7 Smart Panel tool flange interface are also part of the platform.

On safety certifications, Universal Robots states that all g-Series robots are TÜV certified to ISO 10218-1 and UL1740. Teradyne Robotics holds IEC 62443-4-1 ML3 certification for cybersecurity.

"The robots of the AI era must be advanced, not complicated," said Jean-Pierre Hathout, President of the Teradyne Robotics Group. "Gen 7 is an end-to-end redesign of our platform that reduces integration friction and dramatically expands application capabilities."

Gen 7 is on display at IMTS alongside demonstrations from more than 20 ecosystem partners, including Cognex, Schunk, Robotiq, and Inbolt.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• InMed Pharmaceuticals gets Nasdaq equity deficiency notice
• Gauzy wins court approval for debt restructuring, SPD film output to resume